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Purpose: Few studies have evaluated the risk profile of prostate-specific antigen (PSA)-
detected T1cN0M0 prostate cancer, defined as tumors diagnosed by needle biopsy
because of elevated PSA levels without other clinical signs of disease. However, some men
with stageT1cN0M0 prostate cancer may have high-risk disease (HRD), thus experiencing
inferior outcomes as predicted by a risk group stratification model.
Methods:We identified men diagnosed with stageT1cN0M0 prostate cancer from 2004 to
2008 reported to the surveillance, epidemiology, and end results (SEER) program. Multivari-
ate logistic regression was used to model the probability of intermediate-risk-disease (IRD)
(PSA≥10 ng/ml but <20 ng/ml and/or GS 7), and high-risk-disease (HDR) (PSA≥20 ng/ml,
and/or GS≥8), relative to low-risk disease (LRD) (PSA<10 ng/ml and GS≤6), adjusting for
age, race, marital status, median household income, and area of residence.
Results: A total of 70,345 men with PSA-detected T1cN0M0 prostate cancer were iden-
tified. Of these, 47.6, 35.9, and 16.5% presented with low-, intermediate-, and high-risk
disease, respectively. At baseline (50 years of age), risk was higher for black men than for
whites for HRD (OR 3.31, 95% CI 2.85–3.84). The ORs for age (per year) for HRD relative
to LRD were 1.09 (95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for
black men. Further, among a subgroup of men with low PSA (<10 ng/ml)T1cN0M0 prostate
cancer, risk was also higher for black man than for white men at baseline (50 years of age)
(OR 2.70, 95% CI 2.09–3.48).The ORs for age (per year) for HRD relative to LRD were 1.09
(95% CI 1.09–1.10) for white men, and as 1.06 (95% CI 1.05–1.07) for black men.
Conclusion: A substantial proportion of men with PSA-detected prostate cancer as
reported to the SEER program had HRD. Black race and older age were associated with a
greater likelihood of HRD.
Keywords: prostate cancer, race, age, population-study, SEER, screen-detected
INTRODUCTION
Prostate cancer is the most common malignancy in U.S. men.
In 2013 alone, an estimated 241,000 new cancer cases will be
diagnosed and 28,000 deaths will be attributed to prostate can-
cer (1). Current screening methods for prostate cancer include
prostate-specific antigen (PSA) testing and digital rectal exami-
nation, although benefits of the former remain controversial (2,
3). The concern is that early detection and treatment of clinically
insignificant prostate cancer may cause unnecessary side effects
without added benefit.
Ever since FDA approval of PSA as a screening tool, many men
have had a prostate biopsy because of an elevated PSA, despite a
normal digital rectal examination. Prostate cancer diagnosed in
this setting is classified as stage T1c disease based on the Ameri-
can Joint Commission on Cancer (AJCC) (4). Early studies have
shown that stage T1c disease is heterogeneous in its pathological
features. After a retrospective review of 257 patients with stage T1c
prostate cancer who underwent prostatectomy and nodal dissec-
tion from 1987 to 1991, Lerner et al. (5) from the Mayo Clinic
reported that 45% of patients had non-organ confined pT3 dis-
ease and 4% had node positive disease. Of 240 men with stage
T1c disease who underwent radical prostatectomy at Johns Hop-
kins from 1994 to 1996, 28% had extracapsular extension, seminal
vesicle, or lymph node involvement (6). From 1988 to 1998, 638
men with stage T1c prostate cancer underwent radical prostatec-
tomy at Washington University, and 30% had non-organ confined
pT3 or node positive disease (7). Many studies have shown that
adverse pathological features such as pT3 disease (extracapsular
extension and seminal vesicle involvement), high Gleason score
(GS) and positive surgical margins increased the risk of disease
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recurrence resulting in inferior outcomes (8–17). These stud-
ies suggested that some men with stage T1c disease might have
high-risk prostate cancer. However, current PSA screening pro-
tocols are not able to identify clinically significant disease in this
cohort.
The purpose of this study is to provide a contemporary profile
of stage T1c prostate cancer based on demographic features and
a risk stratification scheme developed by D’Amico et al. (18, 19)
that includes stage, GS, and PSA level. This risk stratification has
been validated and widely used, including by the National Com-
prehensive Cancer Network (NCCN). We analyzed demographic
and tumor characteristics of over 70,000 men who, according to
data reported to the Surveillance, Epidemiology, and End Results
(SEER) program (2004–2008), were diagnosed with prostate can-
cer based on an elevated PSA level and without other clinical
signs of disease (stage T1cN0M0). We report the probability of
high-risk prostate cancer in these patients adjusting for character-
istics such as age, race, marital status, median household income,
and area of residence, while taking into account pre-biopsy PSA
levels. These findings may provide important information in
our efforts to develop more effective prostate cancer screening
tools.
MATERIALS AND METHODS
PATIENT DATABASE
Men diagnosed with AJCC stage T1cN0M0 prostate adenocar-
cinoma at age≥ 18 years between 2004 and 2008 and reported
to the SEER 17 Registries were identified. Year 2004 was chosen
as the start year, since it was February 2004 that SEER initiated
collection of detailed T, N, and M staging information. “Death
certificate only” and “autopsy only” cases were excluded. A total of
78,367 cases were identified with stage T1cN0M0 disease. A total
of 70,345 cases had PSA or GS available for analysis.
The youngest man in the cohort with stage T1cN0M0 dis-
ease was 37 years of age. We identified 262,172 men ≥37 years
of age with all stages of prostate cancer between 2004 and
2008. The SEER program provided the number of all men age
≥37 years in SEER catchment area based on 2000 U.S. population
estimates.
Based on PSA levels and GS, we divided cases into the three
risk groups as described by D’Amico et al. (18). Low-risk disease
(LRD) was defined as PSA <10 ng/ml and GS ≤6; intermediate-
risk disease (IRD) as PSA ≥10 and <20 ng/ml and/or GS 7; and
high-risk disease (HRD) as PSA ≥20 ng/ml and/or GS ≥8.
Patient socioeconomic status was evaluated using “median
household income” and “rural-urban continuum code” provided
in the SEER program, as in prior studies (20). Median house-
hold income is an aggregate measure based on county attributes
derived from the 2000 U.S. census. Rural-urban continuum code,
which provides information about potential accessibility to cancer
care, allows classification of counties by population size, degree of
urbanization, and proximity to metropolitan areas. We grouped
patients into three categories by area of residence: within met-
ropolitan areas, adjacent to metropolitan areas, and not adjacent
to metropolitan areas. Marital status at diagnosis was classified
as follows: never-married (single), married, and others (widowed,
divorced, and separated).
STATISTICAL ANALYSIS
The means of continuous variables (e.g., age and median house-
hold income) were compared between groups using t -tests with
unequal variances. Chi-square tests were used to assess differences
in categorical variables (e.g., race and gender) between groups.
Multivariate logistic regression analyses were conducted to model
the probability of developing IRD and HRD. The list of potential
predictors to be included in the models was age, race, marital sta-
tus, median household income, area of residence, and all possible
first-order interactions. The analyses treated “age” as continuous
variable and set 50 year of age as baseline. To select predictors
significantly associated with disease risk, the data set was ran-
domly partitioned into a training and validation data set of equal
sizes (50% of the original data set each). We first ran a backward
model selection procedure on the training data set to identify can-
didate predictors potentially associated with disease risk. Once
this training step was completed, we fitted the identified model to
the validation data set; predictors with p-values smaller than 0.05
were considered significant and included in the final models. This
analysis was performed for the IRD and HRD separately. The final
models were also used to model the probability of developing IRD
and HRD in a subgroup analysis for patients with PSA<10 ng/ml
stage T1cN0M0 prostate cancer. In all of our statistical analyses,
tests were two-sided and the significance level (probability of type-
1 error) was set at 0.05. Analyses were conducted using the SAS
statistical package, version 9.13 (SAS Institute, Cary, NC, USA).
RESULTS
The age distribution of men ≥37 years of age in the SEER catch-
ment areas are shown in Table 1. While 11.8% of men ≥37 years
of age in the SEER catchment area were ≥75 years of age, 24.2%
men with prostate cancer of all stages and 26.1% men with stage
T1cN0M0 prostate cancer were ≥75 years of age. Among all men
diagnosed with prostate cancer (n= 262,172) in the SEER pro-
gram, 78,367 (29.9%) had stage T1cN0M0 disease. The percentage
changed with age, 15.8, 24.6, 35.2, and 32.2% for age groups of
37–49, 50–64, 65–74, and ≥75 years, respectively (Table 1).
Table 1 | Age distribution of men in SEER catchment areas, and men
with prostate cancer of all stages and stageT1cN0M0 specifically.
Age No. of men in
SEER areasa
No. of men with prostate cancer
All
stagesb
T1cN0M0b Percent
(T1cN0M0/
all stage)
37–49 14,983,548 1,550 244 15.8%
50–64 12,929,972 19,646 4,826 24.6%
65–74 4,530,521 18,520 6,510 35.2%
≥75 4,329,573 12,718 4,093 32.2%
aProvided by SEER program using the 2000 U.S. standard population estimates.
bAverage annual number of men with all stage prostate cancer and with stage
T1cN0M0 prostate cancer are defined as crude rates reported by SEER between
2004 and 2008 divided by 5.
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A total of 70,345 men with stage T1cN0M0 prostate cancer had
GS and PSA information available and these men were evaluated
(median age 69 years, range 37–105) (Table 2). There were 11,600
men (16.5%) with HRD. Men with HRD were significantly older
(median age 72, 70, and 67 for HRD, IRD, and LRD respectively,
p< 0.01); more likely to be black (19.4 and 15.6% for black and
white respectively, p< 0.01); less likely to be married (16.7 and
15.5% for never-married and married respectively); and had a
lower median household income (17.7, 16.6, and 15.6% for first,
second, and third tertile respectively, p< 0.01).
Based on age and PSA level, Table 3 shows the distribu-
tion of GS among 70,345 men with stage T1cN0M0 disease. For
example, a 72-year-old man with a PSA of 8 ng/ml stage T1cN0M0
prostate cancer has a 7.2% chance of having GS ≥8 HRD. For an
82-year-old man with the same PSA level, the chance of HRD
is 16.5%.
Older men were more likely to have higher PSA levels at
the time of diagnosis (Figure 1A, p< 0.01). The percentage
of men with PSA ≥20 ng/ml stage T1cN0M0 prostate cancer
increased with age (5.3, 6.4, 7.6, and 13.3% for age groups 37–
49, 50–64, 65–74, and ≥75, respectively). Furthermore, the per-
centage of men with higher GS increased with age (Figure 1B,
p< 0.01). There were 3.6, 6.1, 9.1, and 17.5% men with GS
≥8 stage T1cN0M0 prostate cancer for age groups 37–49, 50–
64, 65–74, and ≥75, respectively. Black men were more likely to
have higher PSA levels than white men at diagnosis (Figure 2A,
p< 0.01). For example, 10.6% of black men and 7.5% of white
men had PSA of ≥20 ng/ml. There was a small but significant
Table 2 | Characteristics of 70,345 men with low-, intermediate-, and high-risk prostate cancer.
Low riska Intermediate riska High riska p-Value
Number of patients 33,472 (47.6%) 25,273 (35.9%) 11,600 (16.5%)
Age, year (median, range) 67 (37–105) 70 (38–98) 72 (38–98) <0.01
<50 720 (68.6%) 248 (23.6%) 81 (7.7%)
50–64 12,819 (58.6%) 6,597 (30.2%) 2,449 (11.2%)
65–74 14,418 (48.6%) 10,869 (36.6%) 4,393 (14.8%)
≥75 5,515 (31.1%) 7,559 (42.6%) 4,677 (26.3%)
Race <0.01
White 26,465 (49.2%) 18,933 (35.2%) 8,366 (15.6%)
Black 4,383 (41.5%) 4,118 (39.0%) 2,051 (19.4%)
Otherb 1,621 (40.8%) 1,511 (38.1%) 839 (21.1%)
Unknown 1,003 (48.7%) 711 (34.5%) 344 (16.7%)
Marital status <0.01
Married 23,308 (49.1%) 16,801 (35.4%) 7,371 (15.5%)
Never-married 3,094 (47.0%) 2,391 (36.3%) 1,099 (16.7%)
Otherc 3,830 (42.2%) 3,475 (38.3%) 1,772 (19.5%)
Unknown 3,240 (45.0%) 2,606 (36.2%) 1,358 (18.9%)
Median household incomed <0.01
First tertile 8,795 (46.1%) 6,919 (36.2%) 3,374 (17.7%)
Second tertile 10,613 (47.2%) 8,149 (36.2%) 3,728 (16.6%)
Third tertile 14,061 (48.9%) 10,205 (35.5%) 4,498 (15.6%)
Area of residence <0.01
Within metro 30,493 (47.8%) 22,948 (36.0%) 10,347 (16.2%)
Adjacent to metro 1,807 (46.0%) 1,390 (35.4%) 731 (18.6%)
Not adjacent to metro 1,138 (44.5%) 910 (35.6%) 510 (19.9%)
Unknown 33 (47.1%) 25 (35.7%) 12 (17.1%)
Median follow up in months (range) 26 (12–59) 25 (1–59) 25 (1–59)
Year of diagnosis p=0.60
2004 6,176 (48.5%) 4,421 (34.7%) 2,146 (16.8%)
2005 5,976 (47.8%) 4,425 (35.4%) 2,104 (16.8%)
2006 7,296 (48.4%) 5,290 (35.1%) 2,489 (16.5%)
2007 7,508 (47.2%) 5,855 (36.8%) 2,527 (15.9%)
2008 6,516 (46.1%) 5,282 (37.4%) 2,334 (16.5%)
aRisk groups: low risk – PSA <10 ng/ml and GS ≤6, intermediate risk – 10 ng/ml≤PSA <20 ng/ml and/or GS=7, high risk – PSA >20 ng/ml, and/or GS ≥8 as defined
by D’Amico (19).
bOther: American Indian, Alaska Native, Asian, and Pacific Islander.
cOther: widowed, divorced, and separated.
dFirst tertile, <$ 42,190; second tertile, $ 42,191–49,820; third tertile, ≥$ 49,821.
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FIGURE 1 | Distribution of PSA (A) and Gleason Score (GS) (B) by age
group among men with stageT1cN0M0 prostate cancer. The difference
in the distribution of PSA (p< 0.01) and GS (p<0.01) among age groups
was evaluated with the two-sided Chi-square test.
difference in GS profile between black and white men (Figure 2B,
p< 0.01).
Multivariate logistic regression analyses identified a significant
interaction between age and race, indicating that risk increased
faster with age among white men compared to blacks for both HRD
and IRD relative to LRD (Table 4). At baseline (50 years of age),
risk was higher among black men than among whites for HRD and
IRD (OR 3.31 and 2.02, 95% CI 2.85–3.84, and 1.81–2.25, respec-
tively). The ORs for age (per year) for HRD and IRD relative to
LRD were estimated as 1.09 and 1.06 respectively (95% CI 1.09–
1.10, 1.05–1.06) for white men, and as 1.06 and 1.04 respectively
(95% CI 1.05–1.07, 1.03–1.04) for black men. Compared to base-
line (50 years of age), the ORs at 75 years of age for HRD and IRD
relative to LRD were estimated as 9.25 (95% CI 8.45–10.13) and
3.97 (95% CI 3.72–4.24) respectively for white men, and as 4.24
(95% CI 3.56–5.04) and 2.58 (95% CI 2.24–2.96) respectively for
black men. Men in the “never-married” category compared with
“married” men were more likely to have HRD and IRD (OR 1.35
and 1.22, 95% CI 1.25–1.46 and 1.15–1.29, respectively), but no
FIGURE 2 | Distribution of PSA (A) and Gleason Score (GS) (B) by white
and black race among men with stageT1cN0M0 prostate cancer. The
difference in the distribution of PSA (p<0.01) and GS (p<0.01) between
white and black men was evaluated with the two-sided Chi-square test.
significant association was observed between median household
income and disease risk.
As one may argue that the elevated PSA levels in the elderly
patients with HRD may be a function of lead-time detection of
younger individuals with lower PSA, we also analyzed age and
racial effect in a subgroup of men with PSA <10 ng/ml stage
T1cN0M0 prostate cancer (Table 5). We found that in this group
of men with low PSA (<10 ng/ml), again, older men were more
likely to have GS≥8 HRD (12.3, 6.6, 4.3, and 1.9% for age groups
≥75, 65–74, 50–64, and 37–49 respectively). Black men were more
likely to have GS ≥8 HRD (7.6 and 6.7% for black and white
men respectively). Multivariate logistic regression analyses for this
cohort of men showed that risk increased faster with age among
white men compared to black men for both HRD and IRD relative
to LRD (Table 6). At baseline (50 years of age), risk was higher
among black men than among whites for HRD and IRD (OR
2.70 and 1.94, 95% CI 2.09–3.48 and 1.70–2.20, respectively). The
OR for age (per year) for patients with GS ≥8 HRD (relative to
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Table 4 | Multivariate logistic regression analyses modeling the probabilities of patients with intermediate-risk disease vs. low-risk disease, and
of patients with high-risk diseases vs. low-risk disease respectively.
Intermediate vs. low riska High vs. low riska
Odds ratio 95% CIb p-Value Odds ratio 95% CIb p-Value
Age (per year)× race
White 1.06 (1.05, 1.06) <0.01 1.09 (1.09, 1.10) <0.01
Black 1.04 (1.03, 1.04) <0.01 1.06 (1.05, 1.07) <0.01
Otherc 1.06 (1.04, 1.07) 0.86 1.08 (1.07, 1.11) 0.27
Race <0.01 <0.01
White – – – – – –
Black 2.02 (1.81, 2.25) <0.01 3.31 (2.85, 3.84) <0.01
Otherc 1.30 (1.06, 1.60) 0.01 1.58 (1.40, 2.46) <0.01
Marital status <0.01 <0.01
Married – – – – – –
Never-married 1.22 (1.15, 1.29) <0.01 1.35 (1.25, 1.46) <0.01
Othersd 1.19 (1.13, 1.26) <0.01 1.34 (1.25, 1.43) <0.01
Median household incomee 0.43 0.42
First tertile – – – – – –
Second tertile 0.98 (0.94, 1.03) 0.50 0.98 (0.92, 1.05) 0.56
Third tertile 0.97 (0.92, 1.02) 0.20 0.96 (0.90, 1.02) 0.20
Area of residence 0.66 <0.01
Within metro – – – – – –
Adjacent to metro 1.00 (0.92, 1.09) 0.93 1.11 (1.00, 1.23) 0.06
Not adjacent to metro 1.05 (0.95, 1.16) 0.37 1.29 (1.13, 1.46) <0.01
aRisk groups: low risk – PSA <10 ng/ml and GS ≤6, intermediate risk – 10 ng/ml≤PSA <20 ng/ml and/or GS=7, high risk – PSA ≥20 ng/ml and/or GS ≥8.
bCl, confidence interval.
cOthers: American Indian, Alaska Native, Asian, and Pacific Islander.
dOther: widowed, divorced, and separated.
eFirst tertile, <$ 42,190; second tertile, $ 42, 191–49,820; third tertile, ≥$ 49,821.
LRD) were 1.09 (95% CI 1.09–1.10) for white men and 1.06 (95%
CI 1.05–1.07) for black men. Compared to baseline 50 years of
age, the ORs for 75-year-old men for HRD and IRD relative to
LRD were estimated as 8.51 (95% CI 7.36–9.86) and 3.25 (95%
CI 3.01–4.51) respectively for white men, and as 4.09 (95% CI
3.05–5.50) and 2.09 (95% CI 1.78–2.46) respectively for black
men.
DISCUSSION
To our knowledge, this is the largest population-based study
focused only on PSA-detected (stage T1cN0M0) prostate cancer
in the U.S. in the contemporary era of widespread PSA testing. A
significant number of men (16.5%) in this cohort had HRD. We
found that men of older age and black race were more likely to
have HRD than younger and white men.
According to the U.S. census, 4.6% of the total U.S. male pop-
ulation in 2010 was ≥75 years of age respectively (21). However,
40.3% of men with HRD were≥75 years of age. Further, 36.8% of
men with PSA<10 ng/ml and GS≥8 stage T1cN0M0 prostate can-
cer were ≥75 years of age. Our finding that older men were more
likely to have HRD, albeit limited to PSA-detected stage T1cN0M0
disease in this survey, is consistent with recently published studies
(22, 23). After evaluating all prostate cancer cases reported to the
SEER program from 1998 to 2007, Scosyrev et al. (22) reported
that men ≥75 years of age were more likely to present with either
metastatic or locally advanced disease, and experienced the highest
prostate cancer-specific mortality. Bechis et al. (23) reviewed the
database of the Cancer of the Prostate Strategic Urologic Research
Endeavor (CaPSURE) and reported that 26% of men age ≥75
had HRD based on the Cancer of the Prostate Risk Assessment
(CAPRA) score. In addition to clinical stage, PSA, and GS, CAPRA
scores take into consideration patient age and percentage of biopsy
cores involved with prostate cancer.
The specific indications for PSA testing and prostate biopsy
could not be confirmed in our series, given the limitations of the
SEER database. Nonetheless, all cases reported to the SEER pro-
gram were diagnosed by a needle biopsy because of an elevated
PSA level with no other clinical signs of disease (AJCC T1cN0M0)
(4). The higher proportion of older men with HRD reported
here cannot be explained by potential bias that older men with
inherently higher PSA levels were more likely to have biopsy. Even
among men with PSA <10 ng/ml stage T1cN0M0 disease, older
men had significant risk of HRD. One of many possible expla-
nations is that older men may harbor aggressive disease that is
not reflected by PSA level. After pathological review of 211 autop-
sied prostate glands from deceased men with no known prostate
cancer at the time of death, Delongchamps et al. (24) reported
older men had significantly larger tumors, higher GS, and were
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Table 5 | Characteristics of 51,919 men with PSA <10 ng/ml stageT1cN0M0 prostate cancer.
Low riska Intermediate riska High riska p-Value
Number of patients 33472 (64.5%) 14857 (28.6%) 3590 (6.9%)
Age, year (median, range) 67 (37–105) 70 (38–95) 72 (44–95) <0.01
<50 720 (80.5%) 157 (17.6%) 17 (1.9%)
50–64 12819 (72.3%) 4138 (23.3%) 766 (4.3%)
65–74 14418 (64.0%) 6628 (29.4%) 1486 (6.6%)
≥75 5515 (51.2%) 3934 (36.5%) 1321 (12.3%)
Race <0.01
White 26465 (65.4%) 11318 (28.0%) 2697 (6.7%)
Black 4383 (59.9%) 2380 (32.5%) 560 (7.6%)
Otherb 1621 (61.2%) 778 (29.4%) 250 (9.4%)
Unknown 1003 (68.4%) 381 (26.0%) 83 (5.7%)
Marital status <0.01
Married 23,308 (65.0%) 10,117 (28.2%) 2,444 (6.8%)
Never-married 3,094 (65.9%) 1,302 (27.7%) 297 (6.3%)
Otherc 3,830 (61.5%) 1,891 (30.4%) 505 (8.1%)
Unknown 3,240 (62.9%) 1,547 (30.4%) 344 (6.8%)
Median household incomed <0.01
First tertile 8,795 (63.9%) 3,972 (28.9%) 996 (7.2%)
Second tertile 10,613 (65.1%) 4,583 (28.1%) 1,108 (6.8%)
Third tertile 14,061 (64.4%) 6,299 (28.8%) 1,486 (6.8%)
Area of residence <0.01
Within metro 30,493 (64.4%) 13,588 (28.7%) 3,263 (6.9%)
Adjacent to metro 1,807 (64.5%) 790 (28.2%) 204 (7.3%)
Not adjacent to metro 1,138 (65.7%) 471 (27.2%) 122 (7.0%)
Year of diagnosis
2004 6,176 (68.2%) 2,317 (25.6%) 563 (6.2%)
2005 5,976 (66.3%) 2,421 (26.9%) 616 (6.8%)
2006 7,296 (65.3%) 3,098 (27.7%) 779 (7.0%)
2007 7,508 (62.8%) 3,597 (30.1%) 845 (7.1%)
2008 6,516 (60.7%) 3,424 (31.9%) 787 (7.3%)
aRisk groups: low risk – PSA <10 ng/ml and GS ≤6, intermediate risk – PSA <10 ng/ml and GS= 7, high risk – PSA <10 ng/ml and GS ≥8.
bOther: American Indian, Alaska Native, Asian, and Pacific Islander.
cOther: widowed, divorced, and separated.
dFirst tertile, <$ 42,190; second tertile, $ 42,191–49,820; third tertile, ≥$ 49,821.
more likely to have extraprostatic extension or microscopic inva-
sion of bladder neck (4). After a prospective review of 268 men with
stage T1c prostate cancer who underwent radical prostatectomy at
seven U.S. medical centers, Southwick et al. (25) noted age was
one of the significant predictors of unfavorable pathological out-
come, including extracapsular extension, seminal vesicle invasion,
invasion of bladder neck/rectum, and lymph node involvement.
Further study is needed to evaluate many confounding factors on
observed age effect.
African Americans have the highest prostate cancer burden
and mortality of any racial group (1). Our study showed that
in the cohort of men with PSA screen-detected stage T1cN0M0
disease, African Americans had a higher likelihood of harboring
HRD than whites, including cohort of men with PSA <10 ng/ml.
Many socioeconomic and intrinsic factors may contribute to such
a racial difference. But even among U.S. service men with equal
access to care, racial difference in prostate cancer risk remains
(26). In an early study among men with non-palpable prostate
cancer (clinical stage T1c disease) who underwent prostatectomy,
Sanchez-Ortiz et al. reported that African American men had
higher GS and greater tumor volume (27). Therefore, prostate
cancer in black men may be biologically different from whites. In
fact, several genetic and biological mechanisms have been identi-
fied that may contribute to the aggressiveness of prostate cancer
in African American men (28–32).
Our study was not designed to address the question of whether
earlier detection would improve survival of men with HRD. Also
to our knowledge, there have been no reported randomized stud-
ies that evaluate the outcome of early intervention vs. active
surveillance for men found to have stage T1cN0M0 prostate can-
cer. There are two UK-based ongoing prostate cancer trials: the
CAP (Comparison Arm for ProtecT) and ProtecT (Prostate Test-
ing for Cancer and Treatment) trials (33) that may help address
issues of screening and treatment, but the results will not be
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Table 6 | Multivariate logistic regression analyses modeling the probabilities of patients with PSA <10 ng/ml intermediate-risk disease vs.
low-risk disease, and of patients with PSA <10 ng/ml high-risk diseases vs. low-risk disease respectively.
Intermediate vs. low riska High vs. low riska
Odds ratio 95% CIb p-Value Odds ratio 95% CIb p-Value
Age (per year)× race
White 1.05 (1.04, 1.05) <0.01 1.09 (1.09, 1.10) <0.01
Black 1.04 (1.04, 1.05) <0.01 1.06 (1.05, 1.07) <0.01
Otherc 1.04 (1.03, 1.06) 0.26 1.08 (1.06, 1.10) 0.26
Race <0.01 <0.01
White – – – – – –
Black 1.94 (1.70, 2.20) <0.01 2.70 (2.09, 3.48) <0.01
Otherc 1.27 (0.99, 1.63) 0.06 1.85 (1.17, 2.91) <0.01
Marital status <0.01 <0.01
Married – – – – – –
Never-married 1.07 (0.99, 1.15) 0.07 1.11 (0.97, 1.27) 0.12
Othersd 1.09 (1.03, 1.16) <0.01 1.18 (1.06, 1.31) <0.01
Median household incomee 0.09 0.45
First tertile – – – – – –
Second tertile 0.95 (0.90, 1.01) 0.12 0.95 (0.85, 1.05) 0.29
Third tertile 1.01 (0.95, 1.07) 0.82 0.99 (0.90, 1.10) 0.90
Area of residence 0.19 0.84
Within metro – – – – – –
Adjacent to metro 0.95 (0.86, 1.04) 0.27 0.98 (0.83, 1.67) 0.84
Not adjacent to metro 0.90 (0.80, 1.02) 0.11 0.94 (0.75, 1.17) 0.57
aRisk groups: low risk – PSA <10 ng/ml and GS ≤6, intermediate risk – PSA <10 ng/ml and GS=7, high risk – PSA <10 ng/ml and GS ≥8.
bCl, confidence interval.
cOthers: American Indian, Alaska Native, Asian, and Pacific Islander.
dOther: widowed, divorced, and separated.
eFirst tertile, <$ 42,190; second tertile, $ 42,191–49,820; third tertile, ≥$ 49,821.
available until 2016. Based on results from many published stud-
ies (34–36) including stage T1cN0M0 disease, it is conceivable
that a subgroup of men may indeed benefit from early detec-
tion and treatment. The challenge at this time is to distinguish
these patients from many men with clinically non-consequential
disease.
Our study has several weaknesses due to the retrospective
design and inherent deficiencies of data reported to the SEER pro-
gram. We had no way to independently verify staging accuracy.
SEER did not provide detailed information about biopsy tem-
plates/schemes. We were not able to analyze patient outcomes due
to the short follow up in the cohort. Further, there was no informa-
tion about patients’ performance status, medical co-morbidities,
voiding symptoms, or family history of prostate cancer in the SEER
database; these factors might have influenced screening decisions.
Eight percent (5,605/70,345) of men in this study had a PSA level
<4 ng/ml. It is unclear why these men proceeded to biopsy, though
likely explanations may include patient preference, family history
of prostate cancer, or incorrect staging.
We used a risk stratification scheme developed by D’Amico et al.
(18, 19) that has been validated and widely used. In addition to
clinical stage, PSA, and GS, there are many other factors that may
influence prostate cancer outcome. These include primary and
secondary GS, tertiary GS (37–41), percentage of positive biopsies
(42–47), or presence of perineural invasion in the biopsy specimen
(48). The SEER database does not provide such important infor-
mation; therefore we limited our risk estimation based on clinical
stage (in this case, stage T1cN0M0), PSA, and GS.
Despite the above limitations, our large population-based study
shows that a substantial proportion of men with PSA-detected
stage T1cN0M0 prostate cancer may have HRD in the contem-
porary era. Older and black men were more likely to have HRD
than younger and white men. Analytic studies with independently
verified staging information are needed to confirm these findings,
and examine clinical outcomes in these men, especially those of
older age and of black race.
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